|
1
|
Banshoya K, Machida A, Kawamura S, Yamada T, Okada R, Kawamoto Y, Kimura H, Shibata S, Hieda Y, Kaneo Y, Tanaka T, Ohnishi M. Development of a Water-Soluble Nanomicellar Formulation Loaded with Trans-Resveratrol Using Polyethylene Glycol Monostearate for the Treatment of Intracerebral Hemorrhage. Pharmaceutics 2024; 16:1462. [PMID: 39598585 PMCID: PMC11597214 DOI: 10.3390/pharmaceutics16111462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Revised: 11/12/2024] [Accepted: 11/14/2024] [Indexed: 11/29/2024] Open
Abstract
Background/Objectives: Trans-resveratrol (Res) has been reported to possess many biological activities, including neuroprotective effects, owing to its anti-inflammatory and antioxidant properties. However, Res has very low water solubility, which limits its therapeutic application. In this work, we formulated water-soluble micellar formulations incorporating Res using polyethylene glycol monostearate (stPEG). Methods: These formulations (stPEG/Res) were developed using five types of stPEG containing 10, 25, 40, 55 and 140 PEG repeat units. The formulations were characterized for Res content, water solubility, particle size, zeta potential, precipitation, biodistribution, and efficacy against neuronal and motor dysfunction in intracerebral hemorrhage (ICH). Results: Intravenous administration of stPEG40/Res, which demonstrated particle size, water solubility, and biodistribution properties suitable for intravenous administration, suppressed neurological and motor dysfunction following in a collagenase-induced ICH mouse model. These effects were inhibited by zinc protoporphyrin-9, an inhibitor of the antioxidant enzyme heme oxygenase-1, suggesting that Res contributes to antioxidant enzyme expression and anti-inflammatory activity. Conclusions: The stPEG/Res micellar formulation developed in this study may offer a promising therapeutic approach for ICH treatment.
Collapse
Affiliation(s)
- Kengo Banshoya
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Aoi Machida
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
- Graduate School of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan
| | - Saki Kawamura
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Tetsuhiro Yamada
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Riko Okada
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Yui Kawamoto
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Hikaru Kimura
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
- Pharmacy Department, Yamaguchi University Hospital, Ube 755-8505, Yamaguchi, Japan
| | - Sachi Shibata
- Faculty of Health and Welfare Science, Okayama Prefectural University, Soja 719-1197, Okayama, Japan;
| | - Yuhzo Hieda
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Yoshiharu Kaneo
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Tetsuro Tanaka
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
| | - Masatoshi Ohnishi
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan; (A.M.); (S.K.); (T.Y.); (R.O.); (Y.K.); (H.K.); (Y.H.); (Y.K.); (T.T.)
- Graduate School of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Hiroshima, Japan
| |
Collapse
|